A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors
Clinical trial NCT02410512 · COMPLETED
Trial details
- NCT number
- NCT02410512
- Sponsor
- Genentech, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-04-24
- Primary completion
- 2019-11-22
- Enrollment
- 610
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.